Drug Manufacturing

Groupe PARIMA approaches drug manufacturing with disciplined GMP execution across all production stages.

Drug Manufacturing banner

Reliable GMP Drug Manufacturing at Every Stage

A manufacturing site built for GMP control, flexibility, and dependable execution.

Groupe PARIMA provides flexible pharmaceutical manufacturing across the full product lifecycle, from clinical production to commercial supply.

Our GMP‑compliant manufacturing facility supports scale‑up, tech transfer, and commercial production under the same rigorous quality systems, regardless of product complexity or batch size.

High‑constraint manufacturing control

Complex drug products demand manufacturing approaches that extend beyond standard GMP execution. At Groupe PARIMA, we meet these requirements through a tightly integrated manufacturing environment where process control and quality oversight operate as a unified system to provide consistency across the full product lifecycle.

Card 01

Hazardous Materials Control

We handle hazardous materials through controlled processes, engineered containment, and trained teams, ensuring operator protection while maintaining product quality and process integrity.

Card 02

Protection for Sensitive Products

Amber‑lit manufacturing environments and inert gas atmospheres support the controlled manufacture of light or oxygen-sensitive formulations.

Card 03

Safe Scale‑Up for Volatile Formulations

Dedicated Class I, Division 1 (1D1) rated explosion‑proof suites support alcohol‑based and other flammable formulations, enabling controlled scale‑up from small clinical batches to production volumes ranging from 5 to 1,600 kg.

Card 04

Standardized Batch Oversight

Integrated quality systems ensure the same level of GMP control and oversight is applied across all manufacturing activities, supporting consistent execution regardless of product complexity or production scale.

Manufacturing designed
for Control and Scale

Pharmaceutical vessels are selected and configured based on formulation and process requirements, enabling critical operations such as mixing, blending, and homogenization to be performed with consistency. Our equipment allows tight control of key process parameters for formulations with narrow operating windows or complex rheological behavior. 

01
Card 01

Integrated Temperature Control

Fully jacketed manufacturing tanks with integrated temperature control systems support diverse product temperature profiles.

02
Card 02

Uniform Mixing and Blending

Sweep and counter‑sweep mixing systems promote formulation uniformity and consistency across a wide range of viscosities.

03
Card 03

Controlled Emulsification Process

High‑shear homogenizers enable controlled emulsification and effective particle size reduction.

04
Card 04

Versatile Secondary Processing

A range of secondary processing equipment, including rotosolvers, top-mounted homogenizers, and colloid mills, supports diverse formulation requirements.

05
Card 05

Enhanced Vacuum Capability

Our equipment permits controlled vacuum conditions during manufacturing to eliminate air entrapment and maintain the homogeneity of finished products.

We embed quality into every manufacturing decision, guiding how processes are designed, executed, and controlled under regulatory compliance and GMP guidelines.

Manufacturing Capability Across Scales

Broad manufacturing capacities reflect our ability to support products from early clinical batches through sustained commercial supply.

5 to 2,500 kg

Batch Sizes

Creams, gels, and ointments across development, scale‑up, and commercial production.

2 to 4,000 kg

Batch Sizes

Liquids and suspensions produced at multiple scales for clinical and commercial needs.

30M Units

Annually Capacity

High‑capacity packaging operations supporting sustained commercial demand.

Resources

Explore resources focused on drug manufacturing that impact process design, scale‑up, and commercial execution.

Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development
Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development

Contact us

Discuss Your Drug Manufacturing Requirements

Contact our team to discuss how our GMP manufacturing capabilities can support your product from development through commercial production.